Allianz Asset Management GmbH Decreases Stake in Biogen Inc. $BIIB

Allianz Asset Management GmbH cut its holdings in Biogen Inc. (NASDAQ:BIIB) by 24.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 396,803 shares of the biotechnology company’s stock after selling 130,257 shares during the quarter. Allianz Asset Management GmbH owned 0.27% of Biogen worth $55,584,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS grew its holdings in shares of Biogen by 6.7% in the second quarter. KLP Kapitalforvaltning AS now owns 166,577 shares of the biotechnology company’s stock worth $20,920,000 after purchasing an additional 10,500 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in Biogen during the 2nd quarter valued at about $225,000. Privium Fund Management B.V. purchased a new stake in Biogen in the 2nd quarter valued at about $2,666,000. Nordea Investment Management AB grew its stake in Biogen by 5.7% in the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after acquiring an additional 6,811 shares in the last quarter. Finally, Pitcairn Co. purchased a new position in shares of Biogen during the second quarter worth approximately $936,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 748 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This trade represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by insiders.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Nature Medicine published pivotal DEVOTE results showing the high‑dose nusinersen regimen produced statistically significant motor and biomarker improvements versus lower dose / untreated comparators; safety was broadly consistent and the regimen is under FDA review with an April 3 PDUFA date — a clear potential revenue and label expansion catalyst for SPINRAZA. Nature Medicine Publishes DEVOTE Results
• Positive Sentiment: RBC Capital issued a buy/outperform view on BIIB, which supports upward price momentum by increasing institutional confidence and may attract more buyers ahead of earnings and the PDUFA decision. Biogen Receives a Buy from RBC Capital
• Neutral Sentiment: Market previews flag Q4 results and guidance as near‑term drivers — MS franchise pressures are a headwind but growth from newer assets (Leqembi, Skyclarys) could help offset declines; earnings delivery will likely drive short‑term volatility. Biogen Reports Q4: Everything You Need To Know Ahead Of Earnings
• Neutral Sentiment: Zacks preview notes new drug dynamics are key heading into Q4 — useful context but not an immediate directional trigger absent surprises in the print or guidance. New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
• Neutral Sentiment: Bernstein maintained a Hold (market‑perform) with a ~$191 target, signaling mixed near‑term fundamentals but acknowledging optional upside from emerging assets — this keeps analyst sentiment balanced. Biogen: Unexciting Near-Term Fundamentals but Optionality in Emerging Assets
• Negative Sentiment: An insider (Priya Singhal) disclosed a sale of 748 shares (~$134k) on Feb 2; small in size but sometimes viewed as a modest negative signal by some investors. Insider Form 4 — Priya Singhal Sale

Biogen Stock Performance

BIIB stock opened at $185.45 on Thursday. Biogen Inc. has a one year low of $110.04 and a one year high of $190.20. The firm has a market cap of $27.21 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 1.48 and a beta of 0.16. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. The firm has a 50-day simple moving average of $176.48 and a two-hundred day simple moving average of $155.92.

Analysts Set New Price Targets

Several research firms have recently weighed in on BIIB. Morgan Stanley lifted their price target on shares of Biogen from $149.00 to $156.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Mizuho lifted their target price on Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. HSBC reissued a “reduce” rating and set a $143.00 price target (down previously from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Wells Fargo & Company lifted their price objective on Biogen from $155.00 to $190.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Finally, Oppenheimer increased their target price on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Eleven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $192.58.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.